Global Onychomycosis Treatment Market Projected to Surpass $5.09 Billion by 2029 with 6.7% Annual Growth

What combination of drivers is leading to accelerated growth in the onychomycosis treatment market?
An uptick in fungal infections is anticipated to spur on the growth of the onychomycosis treatment market. Fungi are the root cause of these microbial diseases and can impact various parts of the body, often leading to specific conditions. Onychomycosis, a particular type of fungal nail infection, is usually managed with oral or topical antifungal treatments to quash the existing fungal expansion and initiate healthy nail growth. An example of this trend was seen in September 2023 when the UK Health Security Agency, a UK government agency, recorded 2,265 yeast-induced bloodstream infections (BSI) shared in 2022 in England by the SGSS. The yeast-related BSI incidence rate saw a slight increase to 4.0 per 100,000 of the population, up from 3.8 per 100,000 in 2021. In the blood samples studied, Candida albicans (40%), Nakaseomyces glabratus (formerly Candida glabrata, 29%), and Candida parapsilosis (13%) were the most frequently found yeast species. This surge in fungal infections is spurring the growth of the onychomycosis treatment market. The escalating prevalence of diabetes is predicted to fuel the growth of the onychomycosis treatment market. Diabetes, a long-lasting health condition that causes high blood sugar levels, elevates the chance of developing onychomycosis and heightens the risk of infection while slowing down the healing process. Topical and laser treatments can safeguard foot health and reduce the probability of future infections. To illustrate, in May 2024, the British Diabetic Association (Diabetes UK) reported that around 4.4 million people in the UK had been diagnosed with diabetes as per the records of 2022-23. Of these cases, approximately 8% were identified with type 1 diabetes, while the vast majority, around 90%, battled type 2 diabetes. The remaining 2% was made up of other lesser-known types of diabetes. Thus, the rising prevalence of diabetes is driving the growth of the onychomycosis treatment market.

Get Your Onychomycosis Treatment Market Report Here:
https://www.thebusinessresearchcompany.com/report/onychomycosis-treatment-global-market-report

What is the projected compound annual growth rate (CAGR) of the onychomycosis treatment market from 2025 to 2034, and what factors influence it?
The market size for onychomycosis treatment has seen considerable growth in the recent past. It is predicted to surge from $3.65 billion in 2024 to $3.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The robust growth in the historic period has been driven by factors such as an increase in fungal infections, an aging populace, heightened public awareness, a rising incidence of onychomycosis, and growing disposable incomes.

The market size for onychomycosis treatment is projected to experience substantial growth in the upcoming years. The market is anticipated to expand to $5.09 billion by 2029, with a compound annual growth rate (CAGR) of 6.7%. The growth expected in this predicted duration can be linked to factors such as a rise in the elderly population, the broadening of telemedicine, combination therapies, enhanced healthcare accessibility, shifts in lifestyle and environmental factors, and a rising incidence of diabetes. The forecast period is expected to see dominant trends such as advancements in dermatology, novel drug delivery systems, customized treatment regimens, advancements in topical treatments, digital health solutions, and the use of laser therapy.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12941&type=smp

How are the latest trends influencing the growth of the onychomycosis treatment market?
In an effort to maintain an edge in the onychomycosis treatment market, prominent corporations are investing in innovating new products like MOB-015 and striving to get them federally approved. In an example of this in June 2023, Moberg Pharma AB, a pharmaceutical firm from Sweden, gained European Union approval for MOB-015. This treatment is designed for adults suffering from mild to severe nail fungal infections. The first global marketing permission for this novel onychomycosis medicine came with this approval. Two Phase 3 trials that backed the approval of MOB-015 showed an increase in mycological cure (76% versus up to 42% for comparators) and a significantly higher total cure rate than the vehicle, all without any serious negative side effects. The topical terbinafine product, MOB-015, facilitates the effective reaching of terbinafine concentrations to the nail and nail bed, eliminating the systemic exposure risk that comes with oral terbinafine treatment.

What are the major segments of the onychomycosis treatment market and their role in driving growth?
The onychomycosis treatment market covered in this report is segmented -

1) By Type: Distal Sublingual Onychomycosis, White Superficial Onychomycosis, Proximal Sublingual Onychomycosis, Candida Onychomycosis, Other Types
2) By Treatment Type: Drugs, Laser Therapy, Photodynamic Therapy
3) By Age Group: 0 To 18 Years, 18 To 39 Years, 40 To 64 Years, 65 Years And Above
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12941

Which regions are key players in the growth of the onychomycosis treatment market?
North America was the largest region in the onychomycosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in onychomycosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Who are the key firms paving the way for growth in the onychomycosis treatment market?
Major companies operating in the onychomycosis treatment market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Hetero Drugs Ltd., Sun Pharmaceutical Industries Limited, Cadila Pharmaceuticals Ltd., Dr. Reddys Laboratories Ltd., Intas Pharmaceuticals Limited, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alkem Laboratories Limited, Jubilant Life Sciences Ltd., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Biocon Limited, Emcure Pharmaceuticals Limited, Alembic Pharmaceuticals Ltd., Laurus Labs Limited, Strides Pharma Science Limited, Aarti Drugs Ltd., NATCO Pharma Ltd., Unichem Laboratories Ltd., Indoco Remedies Ltd., Apex Laboratories Pvt. Ltd., Wockhardt Ltd., Nuray Chemicals Private Limited.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=12941&type=smp

What Is Covered In The Onychomycosis Treatment Global Market Report?

•Market Size Forecast: Examine the onychomycosis treatment market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the onychomycosis treatment market for a structured understanding.
•Key Players Overview: Analyze major players in the onychomycosis treatment market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the onychomycosis treatment market.
•Segment Contributions: Evaluate how different segments drive overall growth in the onychomycosis treatment market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the onychomycosis treatment market.
•Industry Challenges: Identify potential risks and obstacles affecting the onychomycosis treatment market.
•Competitive Landscape: Review strategic developments in the onychomycosis treatment market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.